Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 November 2021 | Story Andrè Damons
Prof Motlalepula Matsabisa
Good news galore. Prof Motlalepula Matsabisa, Professor and Director of Pharmacology at the University of the Free State (UFS), received more good news recently when he was awarded a Visiting Professorship at the Beijing University of Chinese Medicine (BUCM) in Beijing, China, as well as being elected as the Deputy President of the South African Society for Basic and Clinical Pharmacology. Prof Matsabisa was also recommended by Dr Blade Nzimande, Minister of Higher Education, Science and Technology, part of the IBSA technical committee.

Prof Motlalepula Matsabisa, Professor and Director of Pharmacology at the University of the Free State (UFS), received more good news recently when he was awarded a Visiting Professorship at the Beijing University of Chinese Medicine (BUCM) in Beijing, China. This news comes at the same time as the traditional medicine expert has been elected as the Deputy President of the South African Society for Basic and Clinical Pharmacology.

This is, however, not the end of the good news for Prof Matsabisa. Dr Blade Nzimande, Minister of Higher Education, Science and Technology, recommended him to Naledi Pandor, Minister of International Relations and Cooperation, to be part of the India, Brazil and South Africa (IBSA) working group in traditional medicine. As a member of the Department of Science and Innovation (DSI) Indigenous Knowledge-based Bio-Innovation programme, Prof Matsabisa, together with Prof Nceba Gqaleni, is part of the IBSA technical committee. Prof Matsabisa is also part of a technical team for National Department of Health on traditional medicines for the IBSA countries 

Unexpected honours

“I was not expecting any of these honours. It comes as a total shock. To have gone through the stringent evaluation and selection process at the BUCM and made it to the university’s highest award, is an honour. This is recognition of my academic and research quality by my peers on an international level.

“Being elected to lead a society of researchers and clinicians in the field of Pharmacology in the country is further recognition nationally of the academic and research excellence status. These awards coming at the same time is unbelievable. I am proud of the work I do as well as a gesture of support from scientists nationally and internationally and the support from UFS having allowed me to do what I do best academically,” says Prof Matsabisa.

According to him, some of the key expectations for this Visiting Professorship at the BUCM are teaching, to do collaborative research and conduct workshops jointly as well as joint leverage of research funding and co-publications. Prof Matsabisa will now, together with his counterparts at BUCM, discuss and synchronise their teaching and research so they plan the visit to benefit the UFS and the BUCM.

The South African Society for Basic and Clinical Pharmacology’s main activities are to bring pharmacologists together and share new scientific knowledge and developments in the field, explains Prof Matsabisa. The Society is for teaching and training; including research in both basic and clinical pharmacology, to support pharmacology conferences nationally and continentally. “We develop young pharmacologists and are also affiliated to international pharmacology societies. The purpose of the South African Society for Basic and Clinical Pharmacology is to excel and grow the pharmacology field in medicine.”

A good year for pharmacology and the UFS

This has been a good year for him and the team, for pharmacology and the UFS, says Prof Matsabisa. Most recently, Prof Matsabisa and the Department of Pharmacology received a grant of R58 million to establish one of the most advanced modern Pharmacology GLP-accredited research and development laboratories in the country, and possibly in the region. The department has also been awarded an annual Technology and Innovation Agency Platform (TIA) grant of R17 million for the next five years early this year.

“I am able to do what I do and achieve all this because of teamwork. I have a value chain of teams from support staff, cleaners, security, technical and research scientists with me. I have good students, postdoctoral fellows as well as management behind me.

“I hope such an environment can be given to all researchers to do what they do best and be supported fully and genuinely by senior management with decisions that are favourable to growing the institution without any favouritism or prejudice to anyone. It has indeed been a good year with all the funding we received. Watch this space for more.”

Looking forward most to China

Prof Matsabisa says he is looking forward to taking some of his postgraduate students with him to spend time at BUCM for training and conducting research. Says Prof Matsabisa: “I have very good postgraduate research students that need all the support. I look forward to spending a month or so at BUCM teaching BUCM students. I will leave my students there in good hands for 6-12 months per year. I promise, when these students return, they will return with a positive attitude for research and accountability.”

This was the case for him when he got a British scholarship to spend time at GlaxoSmithKline and the University of Bradford in the UK for his PhD. 

Prof Matsabisa hopes to use this Professorship at BUCM to popularise the work of the UFS and to create opportunities for new and upcoming researchers in the field of Pharmacology of Medicinal plants. This is his development plan

News Archive

National Department of Health invests R53.5 million in UFS laboratory
2016-02-04

Description: Dr Derek Litthauer Tags: Dr Derek Litthauer

Dr Derek Litthauer
Photo: Supplied

This year has started off on a high note for Dr Derek Litthauer and his team at the South African National Control Laboratory (NCL) for Biological Products. The National Department of Health has awarded the NCL a contract to the value of R53.5 million to continue testing vaccines for the next three years.

Vaccines are biological medicines used to ensure healthy populations by preventing many diseases. The World Health Organization (WHO) estimates that, worldwide, about 5.2 million children under six years old die annually. Of these deaths, 29% are vaccine preventable. Research has revealed that vaccines prevent about 6 million deaths each year globally. Safe and effective vaccines are essential public health tools, which are strictly regulated internationally. It is the NCL’s responsibility to perform quality control testing on all vaccines to be used on humans in South Africa.

This laboratory, the only one of its kind in Africa, receives samples of vaccines from manufacturers and importers for rigorous evaluation and testing. No vaccine may be used in South Africa without a release certificate issued by the Control Lab, certifying that the vaccine is suitable for human use.

The contract is a commitment to ensuring that only vaccines of the highest quality are used in South Africa.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept